Drug Profile


Alternative Names: AV-299; Ficla; SCH-900105

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AVEO Pharmaceuticals
  • Developer AVEO Oncology; AVEO Pharmaceuticals; University of California at San Francisco; University of Pittsburgh
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Hepatocyte growth factor inhibitors; Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I Acute myeloid leukaemia; Head and neck cancer
  • No development reported Lymphoma; Multiple myeloma; Solid tumours
  • Discontinued Glioblastoma

Most Recent Events

  • 24 Oct 2017 Dana-Farber Cancer Institute and Aveo Oncology plan a phase I trial for Pancreatic cancer (First-line therapy, Combination therapy, Late-stage disease, Metastatic disease) in USA (IV) in November 2017 (NCT03316599)
  • 09 Aug 2017 AVEO Pharmaceuticals plans a phase II trial for Head and neck cancer in the second half of 2017
  • 21 Jun 2017 Phase II development for Non-small cell lung cancer is ongoing in Hong Kong, South Korea, Taiwan and Singapore (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top